title: DNA vaccines for non-infectious diseases: new treatments for tumour and allergy.
abstract: The last decade of DNA vaccine research was characterised by a pioneer spirit and enormous enthusiasm, with a large number of publications demonstrating the usefulness of this approach. Unfortunately, DNA vaccines have not necessarily met the high clinical expectations and a number of complications need to be overcome. In the case of cancer and allergy, the requirements for achieving the objectives are very different. Vaccines against allergies need to suppress or alter an unwanted immune response, while a cancer DNA vaccine has to overcome tolerance and/or immune suppression and initiate a powerful immune response. This review addresses currently used general optimisation strategies for DNA vaccines such as modification of immunisation regimens, improving the delivery systems and using molecular adjuvants. In addition, cancer-specific approaches, such as the stimulation of innate and adaptive immunity with replicase-based DNA vaccines, and targeting non-tumour-associated antigens (TAAs) are discussed. Specifically for the optimisation of DNA vaccination against allergies, procedures such as allergen gene recoding, T helper (Th)1 modulation, and the creation of safe DNA vaccines by gene fragmentation, ubiquitination or using artificial hypoallergens are being analysed. These strategies, individually or in combination, hold the potential of making DNA vaccines useful for application in the clinic.
authors.affiliation: Immunology Group, Institute of Chemistry and Biochemistry, University of Salzburg, Salzburg, Austria.
authors.forename: Wolfgang W
authors.initials: WW
authors.lastname: Leitner
authors.forename: Josef
authors.initials: J
authors.lastname: Thalhamer
mesh_terms: D000276:Adjuvants, Immunologic; D000485:Allergens / Q000627:therapeutic use; D000818:Animals; D016207:Cytokines / Q000235:genetics; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D007115:Immunization Schedule; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000628:therapy*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D000485:Allergens; D016207:Cytokines; D019444:Vaccines, DNA